Menopause management: A cardiovascular risk-based approach

Climacteric

Volumn 13, Issue 4, 2010, Pages 328-339

  Haines, C J ^a   Farrell, E ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Asia; Blood Pressure; Cardiovascular Risk; HRT; Menopause

Indexed keywords

ALGORITHM; ARTICLE; ASIA; BLOOD PRESSURE; BODY MASS; CARDIOLOGIST; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; GYNECOLOGY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MENOPAUSE; OBESITY; PHYSICIAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; WAIST CIRCUMFERENCE; AGE; AGED; CARDIOLOGY; CARDIOVASCULAR DISEASES; COMPLICATION; CONSENSUS; CONSENSUS DEVELOPMENT; ESTROGEN THERAPY; MALE; MIDDLE AGED; PACIFIC ISLANDS; PHYSIOLOGY; RISK FACTOR; WOMEN'S HEALTH;

AGE FACTORS; AGED; ALGORITHMS; ASIA; CARDIOLOGY; CARDIOVASCULAR DISEASES; CONSENSUS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; GYNECOLOGY; HUMANS; HYPERTENSION; MALE; MENOPAUSE; MIDDLE AGED; PACIFIC ISLANDS; RISK FACTORS; WOMEN'S HEALTH;

EID: 77953601250     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903450154     Document Type: Article

References (57)

1. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
2. Polo-Kantola P, Erkkola R. Sleep and the menopause. J Br Menopause Soc 2004;10:145-150
3. Sirola J, Rikkonen T. Muscle performance after the menopause. J Br Menopause Soc 2005;11:45-50
4. Sammartino A, Cirillo D, Mandato VD, Di Carlo C, Nappi C. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy. J Endocrinol Invest 2005;28(10 Suppl):80-84
5. Okobia MN, Bunker CH. Epidemiological risk factors for breast cancer: a review. Niger J Clin Pract 2005;8: 35-42
6. Santoro N, Chervenak JL. The menopause transition. Endocrinol Metab Clin North Am 2004;33:627-636
7. Caufriez A. Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. Ann Endocrinol (Paris) 2007;68:241-250
8. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333
10. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53
11. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978;89:157-161
12. Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the perimenopausal woman: a consensus statement of European cardiologists and gynecologists. Climacteric 2007;10:508-526 (Pubitemid 350211299)
13. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia pacific region. J Hypertens 2003;21:707-716
14. Khor GL. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pacific J Clin Nutr 2001;10:76-80
15. Martiniuk ALC, Lee CMY, Lawes CMM, et al. Asia- Pacific Cohort Studies Collaboration. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007;25:73-79
16. Stampfer MJ, Colditz GA, Willet WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Tenyear follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762
17. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534
18. American Cancer Society. Breast Cancer Facts and Figures 2001-2002. Accessed from: www. cancer.org/ downloads/STT/BrCaFF2001.pdf on February 22nd, 2008
19. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
20. de Lignières B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002;5:332-340
21. Fournier A, Berrino F, Riboli E, Avenel V, Clavel- Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-454 (Pubitemid 40279968)
22. Bray JD, Jelinsky S, Ghatge R, et al. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 2005;97:328-341
23. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13(9 Suppl): S78-86
24. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000;36:780-789
25. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:34-44
26. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A metaanalysis. J Gen Intern Med 2006;21:363-366
27. Gambacciani M, Genazzani AR. From the challenge to the reassessment of the Women's Health Initiative: a personal initiative for women's health. Gynecol Endocrinol 2006;22:115-116
28. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001;CD002978
29. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75: 1065-1079
30. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, AusmanasMK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) study. Maturitas 2005;52:35-51
31. Pines A, Sturdee DW, Birkhä user MH, Schneider HPG, Gambacciani M, Paney N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194 (Pubitemid 46752441)
32. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005;112:3384-3390
33. Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension 2008;51: 952-959
34. Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment and control of hypertension in China. Hypertension 2002;40:920-927
35. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053
36. Vasan RS, Larson MG, Leip EP, et al. Impact of highnormal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-1297
37. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
38. Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003;32:563-572
39. Asia Pacific Cohort Studies Collaboration. Body mass index and cardiovascular disease in the Asia Pacific region: an overview of 33 cohorts involving 310 000 participants. Int J Epidemiol 2004;33:751-758
40. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia: A selected review. Circulation 2008;118:2702-2709
41. Wu Y-F, Liu X-Q, Li X, et al. USA-PRC Collaborative Study of Cardiovascular and Cardiopulmonary Epidemiology Research Group; the China Multicenter Collaborative Study of Cardiovascular Epidemiology (China MUCA) Research Group. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 2006;114:2217-2225
42. Asia Pacific Cohort Studies Collaboration, Patel A, Barzi F, Woodard M, et al. An evaluation of metabolic risks for coronary death in the Asia Pacific region. Diab Res Clin Pract 2006;74:274-281
43. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr 2008;17(Suppl 1):37-42
44. Misra A, Wasir JS, Vikram NK. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition 2005;21:969-976
45. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-1186
46. World Health Organization Western Pacific Region. The Asia-Pacific perspective: Redefining obesity and its treatment. Geneva: World Health Organization, 2000
47. Vitale C, Marazzi G, Volterrani M, Aloisio A, Rosano G, Fini M. Metabolic syndrome. Minerva Med 2006;97: 219-229
48. Rosano GM, Vitale C, Silvestri A, Fini M. The metabolic syndrome in women: implications for therapy. Int J Clin Pract Suppl 2004;Mar:20-25
49. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350 (Pubitemid 32378388)
50. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006;9(Suppl 1):19-27
51. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661
52. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477
53. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684
54. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113: 2425-2434
55. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536
56. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286: 180-187
57. Conroy RM, Pyörä lä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003